Bukwang Pharmaceutical and Novartis Venture Fund were among the latest investors in the developer of T-cell therapies for liquid and solid cancers.

US-based cancer treatment developer ImmPact Bio picked up $111m in a series B round on Thursday from investors including pharmaceutical firms Bukwang Pharmaceutical and Novartis. VenBio Partners, Foresite Capital and Decheng Capital co-led the round, which included Surveyor Capital, OrbiMed and RM Global Partners (RMGP). Novartis took place through its corporate venturing vehicle, Novartis Venture Fund.…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.